Hemrajani Rekha 4

What Happened
Rekha Hemrajani, a director of LB Pharmaceuticals (LBRX), was granted a derivative award of 10,000 shares on June 3, 2026. The award was reported at $0.00 per share (total reported value $0) and is a grant/award rather than a purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed 2026-06-05.
• Transaction type: Grant / derivative award (code A).
• Amount: 10,000 shares; Price on grant: $0.00; Reported value: $0.
• Vesting: Footnote states 100% of the shares underlying the award vest on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continuous service.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context
This is a time-vesting derivative award (e.g., stock option or restricted stock unit style grant) that does not provide immediate market exposure or proceeds to the insider until vesting (and possibly exercise or settlement). Grants are common for compensation and do not necessarily signal buying or selling intent; purchases are generally more direct indicators of insider bullishness.